Qiagen N.V. (QGEN) 26.80 $QGEN
After Yesterday's Rally of 14.51% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Fri Jul 29, 2:15PM CDT
QIAGEN (NASDAQ:QGEN) traded in a range yesterday that spanned from a low of $25.35 to a high of $26.88. Yesterday, the shares gained 14.5%, which took the trading range above the 3-day high of $23.58 on volume of 2.7 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
QGEN: 26.80 (+3.37)
QIAGEN Set to Possibly Pullback After Yesterday's Rally of 14.51%
Comtex SmarTrend(R) - Fri Jul 29, 2:13PM CDT
QIAGEN (NASDAQ:QGEN) traded in a range yesterday that spanned from a low of $25.35 to a high of $26.88. Yesterday, the shares gained 14.5%, which took the trading range above the 3-day high of $23.58 on volume of 2.7 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
QGEN: 26.80 (+3.37)
QIAGEN Reports Results for Second Quarter of 2016; Increased Commitment to Return $300 Million of Capital to Shareholders by End-2017
PR Newswire - Thu Jul 28, 3:05PM CDT
-- Q2 2016 results show QIAGEN delivering on goals for acceleration during the year
QGEN: 26.80 (+3.37)
Bioinformatics Leaders to Discuss QIAGEN Biomedical Genomics Solution for NGS Researchers
PRWeb - Wed Jul 27, 9:17PM CDT
QIAGEN N.V. is sponsoring a new, free educational webinar titled "Reference Architectures for the QIAGEN Biomedical Genomics Solution." The conversation will feature joint discussion between key bioinformatics industry leaders and will be pertinent to NGS researchers who need to cost-effectively scale up their genome analysis workflows. The free webinar will be presented on August 2, 2016, at 8 am PT/11 am ET.
QGEN: 26.80 (+3.37)
QIAGEN Launches "Digital NGS" Solutions with Unique Molecular Index Technology to Reliably Detect All Genetic Variation
PR Newswire - Wed Jul 27, 3:07PM CDT
QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced the launch of a comprehensive portfolio of novel QIAseq NGS panels based on a new and proprietary "Digital NGS" technology allowing unbiased, accurate quantification of DNA, RNA and miRNA with next-generation sequencing (NGS). Digital NGS leverages a novel unique Molecular Index Technology enabling more accurate quantification and detection of molecular variants across all sequencing platforms.
QGEN: 26.80 (+3.37)
QIAGEN Launches Novel Integrated System for Collection, Stabilization, Transport, Storage and Isolation of Circulating Cell-free DNA
PR Newswire - Wed Jul 27, 3:05PM CDT
PAXgene Blood ccfDNA enhances handling and workflow convenience for liquid biopsy applications in prenatal testing and cancer research
QGEN: 26.80 (+3.37)
QIAGEN N.V. to Report Second Quarter and First Half of 2016 Results
PR Newswire - Thu Jul 14, 4:14AM CDT
QIAGEN N.V. (Nasdaq: QGEN) (Frankfurt: QIA) plans as previously announced to release its report on results for the second quarter and first half of 2016 on Thursday, July 28, at approximately 22:00 Central European Time (CET) / 16:00 Eastern Time (ET). A conference call is planned for Friday, July 29, at 15:30 CET / 9:30 ET hosted by Peer M. Schatz, Chief Executive Officer, and Roland Sackers, Chief Financial Officer.
QGEN: 26.80 (+3.37)
QIAGEN Announces Successful Completion of Tender Offer for Shares in Exiqon
PR Newswire - Thu Jun 23, 4:45AM CDT
QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced the successful completion of the conditional, voluntary public tender offer for the shares in Exiqon A/S, a world leader in RNA technology. The extended Offer Period expired yesterday, on 22 June 2016, at 23.59 (CET).
QGEN: 26.80 (+3.37)
Qiagen's Q1 Results Hit by Currency, Competition Rife
Zacks Equity Research - Zacks Investment Research - Tue Jun 21, 8:32AM CDT
Qiagen (QGEN) is facing increasing competition from firms that provide pre-analytical solutions and other products.
BSX: 24.28 (-0.06), BAX: 48.02 (-0.20), LMAT: 17.20 (+0.61), QGEN: 26.80 (+3.37)
Active Equities to Watch in the Services Sector -- Booz Allen Hamilton Holding, Qiagen, INC Research Holdings, and Myriad Genetics
PR Newswire - Fri Jun 17, 7:20AM CDT
On Thursday, June 16, 2016, the NASDAQ Composite ended the trading session at 4,844.92, up 0.21%; the Dow Jones Industrial Average advanced 0.53% to finish at 17,733.10; and the S&P 500 closed at 2,077.99, up 0.31%. The gains were broad based as seven out of nine sectors ended the session in positive. Stock-Callers.com has initiated coverage on the following equities: Booz Allen Hamilton Holding Corporation (NYSE: BAH), Qiagen N.V. (NASDAQ: QGEN), INC Research Holdings Inc. (NASDAQ: INCR), and Myriad Genetics Inc. (NASDAQ: MYGN). Learn more about these stocks by accessing their free trade alerts at:
MYGN: 30.98 (-1.09), BAH: 30.88 (-0.40), INCR: 44.51 (-0.46), QGEN: 26.80 (+3.37)
Qiagen???s QIAsure Test to Determine Cervical Cancer Risks
Zacks Equity Research - Zacks Investment Research - Wed Jun 15, 7:33AM CDT
Qiagen's (QGEN) QIAsure accurately stratifies cervical cancer risk, which offers highly sensitive and specific results for patients and clinicians.
BAX: 48.02 (-0.20), LMAT: 17.20 (+0.61), QGEN: 26.80 (+3.37), NUVA: 62.20 (+0.18)
QIAGEN Changes Offer Conditions for Acquisition of Shares in Exiqon A/S
PR Newswire - Wed Jun 08, 9:13AM CDT
QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced its decision to change the offer conditions for the acquisition of shares in Exiqon A/S, reducing the threshold from 90% to 89.20%. All other terms and conditions remain unchanged. In line with the Danish Takeover Order, which requires the extension of an offer period in case of changing offer terms and conditions, QIAGEN N.V. is further extending the offer period, which will now expire on 22 June 2016 at 23:59 (CET).
QGEN: 26.80 (+3.37)
QIAGEN Announces Second Offer Extension for the Acquisition of Shares in Exiqon A/S
PR Newswire - Fri Jun 03, 8:30AM CDT
QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced another extension of the Offer Period for the acquisition of Exiqon A/S, a world leader in RNA technology. On 18 April 2016, QIAGEN N.V. had published a conditional, voluntary public tender offer for the shares in Exiqon A/S, in which the shareholders were offered a cash amount of DKK 18 for each share held in Exiqon A/S. This Offer Period had been extended on 19 May 2016, its terms and conditions remained unchanged. In accordance with the Offer, the extended Offer Period expired yesterday on 2 June 2016 at 23.59 (CET).
QGEN: 26.80 (+3.37)
QIAGEN Forms Lung Cancer Expert Alliance
PR Newswire - Thu Jun 02, 3:05PM CDT
QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced the formation of a global consortium of international lung cancer experts who will advise the company on the design of new next-generation sequencing (NGS) gene panels and associated workflows that target lung cancer-specific mutations.
QGEN: 26.80 (+3.37)
QIAGEN Launches Liquid Biopsy Workflow for GeneReader NGS System
PR Newswire - Wed Jun 01, 3:05PM CDT
QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced the launch of its liquid biopsy workflow for clinical cancer research using QIAGEN's GeneReader NGS System for next-generation sequencing (NGS). The Actionable Insights Tumor Panel, a member of the growing family of GeneRead QIAact Panels, is the industry's first complete Sample to Insight NGS solution for both non-invasive liquid biopsies and FFPE tissue samples. The panel is now optimized for NGS analysis of blood plasma using proven automated QIAGEN sample technologies for circulating cell-free DNA (cfDNA), enabling both tumor characterization and monitoring of cancer resistance markers as a complement to initial tissue biopsies.
QGEN: 26.80 (+3.37)
QIAGEN Integrates Quality Control Tools into GeneReader NGS System
PR Newswire - Tue May 31, 3:05PM CDT
QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced that an extensive package consisting of a quality control set and verification data will be offered with its GeneReader NGS System, reinforcing the proven accuracy of its next-generation sequencing (NGS) workflow and facilitating system setup, quality assurance and training for laboratories. QIAGEN has incorporated the Horizon Discovery Group's industry-standard reference control data set into the GeneReader NGS workflow to support clinical cancer research users from Sample to Insight.
QGEN: 26.80 (+3.37)
Qiagen, Therawis Diagnostics to Develop Breast Cancer Test
Zacks Equity Research - Zacks Investment Research - Fri May 27, 6:47AM CDT
With the global cancer diagnostic market expected to grow at a CAGR of 7.6% to $168.6 billion by 2020, we expect Qiagen (QGEN) to garner higher profits on account of this collaboration.
BSX: 24.28 (-0.06), SRDX: 27.43 (+1.58), BAX: 48.02 (-0.20), QGEN: 26.80 (+3.37)
QIAGEN Partners to Develop Predictive Tests in Oncology
PR Newswire - Wed May 25, 3:05PM CDT
QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced that the company has entered into a licensing and co-development agreement with Therawis Diagnostics GmbH to develop and commercialize predictive assays in oncology. An initial project will be to develop and market PITX2 as a marker to predict effectiveness of anthracycline treatment in triple negative and other high-risk breast cancer patients.
QGEN: 26.80 (+3.37)
QIAGEN Extends Tender Offer Period for Acquisition of Exiqon A/S
PR Newswire - Thu May 19, 9:30AM CDT
QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced the extension of the offer period for the acquisition of Exiqon A/S, a world leader in RNA technology. On 18 April 2016, QIAGEN had published a conditional, voluntary public tender offer for the shares in Exiqon, in which the shareholders of Exiqon were offered a cash amount of DKK 18 for each share they held in Exiqon. In accordance with the Offer, the Offer Period expired yesterday on 18 May 2016 at 23.59 (CET).
QGEN: 26.80 (+3.37)
After Yesterday's Rally of 14.51% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Fri Jul 29, 2:15PM CDT
QIAGEN (NASDAQ:QGEN) traded in a range yesterday that spanned from a low of $25.35 to a high of $26.88. Yesterday, the shares gained 14.5%, which took the trading range above the 3-day high of $23.58 on volume of 2.7 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
QGEN: 26.80 (+3.37)
QIAGEN Set to Possibly Pullback After Yesterday's Rally of 14.51%
Comtex SmarTrend(R) - Fri Jul 29, 2:13PM CDT
QIAGEN (NASDAQ:QGEN) traded in a range yesterday that spanned from a low of $25.35 to a high of $26.88. Yesterday, the shares gained 14.5%, which took the trading range above the 3-day high of $23.58 on volume of 2.7 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
QGEN: 26.80 (+3.37)
QIAGEN Reports Results for Second Quarter of 2016; Increased Commitment to Return $300 Million of Capital to Shareholders by End-2017
PR Newswire - Thu Jul 28, 3:05PM CDT
-- Q2 2016 results show QIAGEN delivering on goals for acceleration during the year
QGEN: 26.80 (+3.37)
Bioinformatics Leaders to Discuss QIAGEN Biomedical Genomics Solution for NGS Researchers
PRWeb - Wed Jul 27, 9:17PM CDT
QIAGEN N.V. is sponsoring a new, free educational webinar titled "Reference Architectures for the QIAGEN Biomedical Genomics Solution." The conversation will feature joint discussion between key bioinformatics industry leaders and will be pertinent to NGS researchers who need to cost-effectively scale up their genome analysis workflows. The free webinar will be presented on August 2, 2016, at 8 am PT/11 am ET.
QGEN: 26.80 (+3.37)
QIAGEN Launches "Digital NGS" Solutions with Unique Molecular Index Technology to Reliably Detect All Genetic Variation
PR Newswire - Wed Jul 27, 3:07PM CDT
QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced the launch of a comprehensive portfolio of novel QIAseq NGS panels based on a new and proprietary "Digital NGS" technology allowing unbiased, accurate quantification of DNA, RNA and miRNA with next-generation sequencing (NGS). Digital NGS leverages a novel unique Molecular Index Technology enabling more accurate quantification and detection of molecular variants across all sequencing platforms.
QGEN: 26.80 (+3.37)
QIAGEN Launches Novel Integrated System for Collection, Stabilization, Transport, Storage and Isolation of Circulating Cell-free DNA
PR Newswire - Wed Jul 27, 3:05PM CDT
PAXgene Blood ccfDNA enhances handling and workflow convenience for liquid biopsy applications in prenatal testing and cancer research
QGEN: 26.80 (+3.37)
QIAGEN N.V. to Report Second Quarter and First Half of 2016 Results
PR Newswire - Thu Jul 14, 4:14AM CDT
QIAGEN N.V. (Nasdaq: QGEN) (Frankfurt: QIA) plans as previously announced to release its report on results for the second quarter and first half of 2016 on Thursday, July 28, at approximately 22:00 Central European Time (CET) / 16:00 Eastern Time (ET). A conference call is planned for Friday, July 29, at 15:30 CET / 9:30 ET hosted by Peer M. Schatz, Chief Executive Officer, and Roland Sackers, Chief Financial Officer.
QGEN: 26.80 (+3.37)
QIAGEN Announces Successful Completion of Tender Offer for Shares in Exiqon
PR Newswire - Thu Jun 23, 4:45AM CDT
QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced the successful completion of the conditional, voluntary public tender offer for the shares in Exiqon A/S, a world leader in RNA technology. The extended Offer Period expired yesterday, on 22 June 2016, at 23.59 (CET).
QGEN: 26.80 (+3.37)
Qiagen's Q1 Results Hit by Currency, Competition Rife
Zacks Equity Research - Zacks Investment Research - Tue Jun 21, 8:32AM CDT
Qiagen (QGEN) is facing increasing competition from firms that provide pre-analytical solutions and other products.
BSX: 24.28 (-0.06), BAX: 48.02 (-0.20), LMAT: 17.20 (+0.61), QGEN: 26.80 (+3.37)
Active Equities to Watch in the Services Sector -- Booz Allen Hamilton Holding, Qiagen, INC Research Holdings, and Myriad Genetics
PR Newswire - Fri Jun 17, 7:20AM CDT
On Thursday, June 16, 2016, the NASDAQ Composite ended the trading session at 4,844.92, up 0.21%; the Dow Jones Industrial Average advanced 0.53% to finish at 17,733.10; and the S&P 500 closed at 2,077.99, up 0.31%. The gains were broad based as seven out of nine sectors ended the session in positive. Stock-Callers.com has initiated coverage on the following equities: Booz Allen Hamilton Holding Corporation (NYSE: BAH), Qiagen N.V. (NASDAQ: QGEN), INC Research Holdings Inc. (NASDAQ: INCR), and Myriad Genetics Inc. (NASDAQ: MYGN). Learn more about these stocks by accessing their free trade alerts at:
MYGN: 30.98 (-1.09), BAH: 30.88 (-0.40), INCR: 44.51 (-0.46), QGEN: 26.80 (+3.37)
Qiagen???s QIAsure Test to Determine Cervical Cancer Risks
Zacks Equity Research - Zacks Investment Research - Wed Jun 15, 7:33AM CDT
Qiagen's (QGEN) QIAsure accurately stratifies cervical cancer risk, which offers highly sensitive and specific results for patients and clinicians.
BAX: 48.02 (-0.20), LMAT: 17.20 (+0.61), QGEN: 26.80 (+3.37), NUVA: 62.20 (+0.18)
QIAGEN Changes Offer Conditions for Acquisition of Shares in Exiqon A/S
PR Newswire - Wed Jun 08, 9:13AM CDT
QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced its decision to change the offer conditions for the acquisition of shares in Exiqon A/S, reducing the threshold from 90% to 89.20%. All other terms and conditions remain unchanged. In line with the Danish Takeover Order, which requires the extension of an offer period in case of changing offer terms and conditions, QIAGEN N.V. is further extending the offer period, which will now expire on 22 June 2016 at 23:59 (CET).
QGEN: 26.80 (+3.37)
QIAGEN Announces Second Offer Extension for the Acquisition of Shares in Exiqon A/S
PR Newswire - Fri Jun 03, 8:30AM CDT
QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced another extension of the Offer Period for the acquisition of Exiqon A/S, a world leader in RNA technology. On 18 April 2016, QIAGEN N.V. had published a conditional, voluntary public tender offer for the shares in Exiqon A/S, in which the shareholders were offered a cash amount of DKK 18 for each share held in Exiqon A/S. This Offer Period had been extended on 19 May 2016, its terms and conditions remained unchanged. In accordance with the Offer, the extended Offer Period expired yesterday on 2 June 2016 at 23.59 (CET).
QGEN: 26.80 (+3.37)
QIAGEN Forms Lung Cancer Expert Alliance
PR Newswire - Thu Jun 02, 3:05PM CDT
QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced the formation of a global consortium of international lung cancer experts who will advise the company on the design of new next-generation sequencing (NGS) gene panels and associated workflows that target lung cancer-specific mutations.
QGEN: 26.80 (+3.37)
QIAGEN Launches Liquid Biopsy Workflow for GeneReader NGS System
PR Newswire - Wed Jun 01, 3:05PM CDT
QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced the launch of its liquid biopsy workflow for clinical cancer research using QIAGEN's GeneReader NGS System for next-generation sequencing (NGS). The Actionable Insights Tumor Panel, a member of the growing family of GeneRead QIAact Panels, is the industry's first complete Sample to Insight NGS solution for both non-invasive liquid biopsies and FFPE tissue samples. The panel is now optimized for NGS analysis of blood plasma using proven automated QIAGEN sample technologies for circulating cell-free DNA (cfDNA), enabling both tumor characterization and monitoring of cancer resistance markers as a complement to initial tissue biopsies.
QGEN: 26.80 (+3.37)
QIAGEN Integrates Quality Control Tools into GeneReader NGS System
PR Newswire - Tue May 31, 3:05PM CDT
QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced that an extensive package consisting of a quality control set and verification data will be offered with its GeneReader NGS System, reinforcing the proven accuracy of its next-generation sequencing (NGS) workflow and facilitating system setup, quality assurance and training for laboratories. QIAGEN has incorporated the Horizon Discovery Group's industry-standard reference control data set into the GeneReader NGS workflow to support clinical cancer research users from Sample to Insight.
QGEN: 26.80 (+3.37)
Qiagen, Therawis Diagnostics to Develop Breast Cancer Test
Zacks Equity Research - Zacks Investment Research - Fri May 27, 6:47AM CDT
With the global cancer diagnostic market expected to grow at a CAGR of 7.6% to $168.6 billion by 2020, we expect Qiagen (QGEN) to garner higher profits on account of this collaboration.
BSX: 24.28 (-0.06), SRDX: 27.43 (+1.58), BAX: 48.02 (-0.20), QGEN: 26.80 (+3.37)
QIAGEN Partners to Develop Predictive Tests in Oncology
PR Newswire - Wed May 25, 3:05PM CDT
QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced that the company has entered into a licensing and co-development agreement with Therawis Diagnostics GmbH to develop and commercialize predictive assays in oncology. An initial project will be to develop and market PITX2 as a marker to predict effectiveness of anthracycline treatment in triple negative and other high-risk breast cancer patients.
QGEN: 26.80 (+3.37)
QIAGEN Extends Tender Offer Period for Acquisition of Exiqon A/S
PR Newswire - Thu May 19, 9:30AM CDT
QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced the extension of the offer period for the acquisition of Exiqon A/S, a world leader in RNA technology. On 18 April 2016, QIAGEN had published a conditional, voluntary public tender offer for the shares in Exiqon, in which the shareholders of Exiqon were offered a cash amount of DKK 18 for each share they held in Exiqon. In accordance with the Offer, the Offer Period expired yesterday on 18 May 2016 at 23.59 (CET).
QGEN: 26.80 (+3.37)
